Stay updated with breaking news from Third Point Ventures. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Cancer drug developer Xilio Therapeutics and Ventyx Biosciences, a company with drug candidates in cancer and autoimmune diseases, are the latest life science companies to go public. They’ll use proceeds from their respective IPOs to continue clinical development of drugs being positioned as competitors to drugs from big pharmaceutical companies.
Press release content from PR Newswire. The AP news staff was not involved in its creation.
/cloudfront-us-east-2.images.arcpublishing.com/reuters/PRT5TCNOUFJHVDLYNXLUMZRKCY.jpg)
The German online bank N26 said on Monday that it had completed a $900 million fundraising round that valued the company at more than $9 billion.
Maximilian tayenthal: . ⭐ Crowdfund Insider: Global Fintech News, including Crowdfunding, Blockchain and more.
/PRNewswire/ -- N26 GmbH ("N26") today announced its record-breaking $900+ million Series E funding round. The recent funding increases the company's valuation...